ANNX
NASDAQ · Biotechnology
Annexon Inc
$4.33
+0.14 (+3.34%)
Open$4.26
Previous Close$4.19
Day High$4.52
Day Low$4.16
52W High$7.18
52W Low$2.54
Volume—
Avg Volume3.30M
Market Cap799.08M
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+842.5% upside
Current
$4.33
$4.33
Target
$40.81
$40.81
$23.52
$40.81 avg
$51.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 226.99M | 205.43M | 221.74M |
| Net Income | -28,556,645 | -21,219,491 | -26,718,856 |
| Profit Margin | -12.6% | -10.3% | -12.1% |
| EBITDA | -33,644,452 | -28,464,345 | -32,841,743 |
| Free Cash Flow | -13,512,889 | -15,079,405 | -14,899,369 |
| Rev Growth | +7.5% | +20.0% | +0.3% |
| Debt/Equity | 0.32 | 0.38 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |